Alexion Korea selects Wolman disease treatment as first drug to introduce
Alexion, a U.S. rare disease pharmaceutical company getting ready for its Korean branch, has decided the first pharmaceutical product to introduce in the domestic market.
It is Kanuma(sebelipase- α), a new biomedicine for lysosomal acid lipase deficiency(LAL-D), also known as Wolman disease.
On...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
